COVID-19 Update: What the Doctors Don’t Tell You with Dr. Ajay Gupta

As much as modern technology and science try to alleviate human suffering, the world has been plagued by numerous health problems afflicting the lives of people. Due to COVID-19, the rate of mortality increased resulting in widespread medical and economic challenges. 

Our body has interferon proteins that are part of the natural defenses. They work by interfering with the virus to enter the body by activating the body’s immune system. This is one of the first lines of defense the human body has when it gets infected with COVID-19 but unfortunately, this is not enough.

According to WHO, as of November 2021, there have been approximately 200 million confirmed cases of COVID-19. For COVID-19 medications, Remdesivir is one of the few drugs approved by the FDA to treat COVID-19 yet researchers are still evaluating which drug works best to fight the global pandemic.

In this episode, Dr. Dung Trinh is joined by Dr. Ajay Gupta, an inventor, and innovator who has investigated Ramatroban, new immunotherapy with a potential treatment for COVID-19. Though still under development, early-phase clinical trials and studies have been promising. 

Learn more about the potential of this medication in Episode 9!

Memorable Quotes:

When there’s a new drug, it takes a lot of clinical trials to ensure that the drug is not just going to be effective but more importantly, it is going to be safe. - Dr. Ajay GuptaNew medications for Covid have to undergo multiple phases of clinical trials but there isn’t always funding for these needed studies. - Dr. Dung Trinh

Other Resources:

[email protected] - Dr. Ajay Gupta

Important Points:

The severity of illness from COVID-19 infection depends on how the body reacts to the virus.As humans age, we produce more Prostaglandin d2 (PGD2). When infected with a virus, the production of PGD2 increases further and suppresses interferons - one of the first immune responders of the body.

About the Guest:

Ajay Gupta, MD is an inventor who currently develops Ramatroban, a PGD2-CRTH2 antagonist, immunotherapy for COVID-19. He is a nephrologist and basic and clinical scientist, the Section Head of Pediatric Epilepsy at Cleveland Clinic, currently the Clinical Professor of Medicine at University of California, Irvine - College of Medicine, and President and Chief Scientific Officer of KARE Biosciences, 

About the Host:

Dung Trinh, MD is the Chief Medical Officer of Irvine Clinical Research, medical missionary with TongueOut Medical Missions, and holds leadership positions with multiple healthcare organizations in Orange County. 

Connect with Dr. Trinh:

FacebookLinkedInYouTube

A Team Dklutr Production